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Abstract
Objective: To conduct a preliminary evaluation of the utility and reliability of a diagnostic tool for HIV-associated dementia
(HAD) for use by primary health care workers (HCW) which would be feasible to implement in resource-limited settings.
Background: In resource-limited settings, HAD is an indication for anti-retroviral therapy regardless of CD4 T-cell count.
Anti-retroviral therapy, the treatment for HAD, is now increasingly available in resource-limited settings. Nonetheless, HAD
remains under-diagnosed likely because of limited clinical expertise and availability of diagnostic tests. Thus, a simple
diagnostic tool which is practical to implement in resource-limited settings is an urgent need.
Methods: A convenience sample of 30 HIV-infected outpatients was enrolled in Western Kenya. We assessed the sensitivity
and specificity of a diagnostic tool for HAD as administered by a primary HCW. This was compared to an expert clinical
assessment which included examination by a physician, neuropsychological testing, and in selected cases, brain imaging.
Agreement between HCW and an expert examiner on certain tool components was measured using Kappa statistic.
Results: The sample was 57% male, mean age was 38.6 years, mean CD4 T-cell count was 323 cells/mL, and 54% had less
than a secondary school education. Six (20%) of the subjects were diagnosed with HAD by expert clinical assessment. The
diagnostic tool was 63% sensitive and 67% specific for HAD. Agreement between HCW and expert examiners was poor for
many individual items of the diagnostic tool (K = .03–.65). This diagnostic tool had moderate sensitivity and specificity for
HAD. However, reliability was poor, suggesting that substantial training and formal evaluations of training adequacy will be
critical to enable HCW to reliably administer a brief diagnostic tool for HAD.
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Introduction
HIV-associated dementia (HAD) is an indication for initiating
antiretroviral therapy regardless of CD4 T-cell count according to
World Health Organization (WHO) guidelines (a WHO Stage IV
diagnosis [1]. However, HAD is likely under-diagnosed in routine
clinical practice in resource-limited settings [2]. Furthermore,
HAD is still a clinically important disorder in resource-limited
settings where many individuals present with advanced HIV
disease. In research studies from sub-Saharan Africa, the
prevalence of HAD ranges from 2.5%–54% [3–10]; these
estimates vary widely likely due to differences in the sampled
populations and methods for assessment of cognitive impairment.
In contrast, the incidence of HAD in more developed regions has
decreased dramatically since ART became widely available [11–
14].
Focusing on the diagnosis of HAD as opposed to milder forms
of HIV-associated neurocognitive disorders (HAND) is critical in
settings where decisions about whether to initiate ART are
frequently made based on WHO criteria alone and where ART
treatment is available only to those with the greatest need—
individuals with very low CD4 T-cell counts and/or WHO Stage
III and IV diagnoses. Since HAD typically improves with ART
[15–17], and availability of ART is increasing even in resource-
limited settings, identification of individuals with HAD can be of
great importance to improve health outcomes. However, the
diagnosis of HAD remains a challenge in HIV outpatient primary
care settings in resource-limited regions [2]. Potential reasons for
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this include: a lack of specialized personnel and diagnostic tests,
and the inherent difficulties in making a clinical diagnosis of a
complex disorder.
Several brief screening tests, like the International HIV
Dementia Scale (IHDS), were developed to identify individuals
with HAND in resource-limited settings. The IHDS has been
demonstrated to be useful in detecting HAND in settings where
screening is conducted by trained physicians and referral to a
specialist is an option [9]. However, specialized personnel are rare
in low income countries. In Kenya the median number of
neurologists per 100,000 population is 0.03 as compared to 2.96 in
high-income countries [18]; similarly, there are only 0.14
physicians per 1,000 population in Kenya as compared to the
United States where the ratio is 2.56 [19].
In addition to highly specialized clinical expertise, in developed
regions, the diagnosis of HAD often entails imaging of the brain,
lumbar puncture, and in milder cases, neuropsychological testing.
Diagnostic tests such as Computed Tomography (CT) of the head
are widely available but unaffordable in Kenya, while magnetic
resonance imaging (MRI) is even less affordable and only available
in the capital city, Nairobi [20]. There are only two neuropsy-
chologists in Kenya (both in private practice) [20]. Thus,
neuropsychological testing is essentially unavailable, and, while
some culturally specific normative data has recently become
available for other sub-Saharan African populations, no published
normative data exists for Kenyans [21,22].
In summary, in resource-limited settings, non-physician health
care workers (HCW) are the first and often the only health care
provider available for a majority of HIV-infected individuals [23]
and diagnostic tests are very limited. Therefore, our goal was to
develop a simple diagnostic tool to identify individuals with
HAD—individuals who should be started on ART regardless of
their CD4 T-cell count. Furthermore, we felt it was important to
develop a tool which would be feasible to implement in
decentralized resource-limited settings. The diagnostic tool should
not require referral to a specialist or additional diagnostic tests,
should only require minimal additional training, and should be
reliably administered by primary HCW. We created a diagnostic
tool designed to guide a HCW through a clinical assessment for
HAD; the tool includes a review of cognitive symptoms, a
neurological examination to screen out individuals with focal
neurological findings, cognitive tests to identify individuals with
impairment, and an assessment of functional status. Here we
report on challenges and lessons learned during pilot testing of this
diagnostic tool for HAD designed for use by non-physician
primary HCW in Nyanza province, Western Kenya.
Methods
Objectives
The objective of this study was to conduct a preliminary
evaluation of the utility and reliability of a diagnostic tool for HAD
designed for use by non-physician primary HCW.
Participants
A convenience sample of 30 adults was recruited from an
outpatient HIV care and treatment program run by Family AIDS
Care and Education Services (FACES) in Kisumu, a city in
Western Kenya, between September and October 2009. Potential
participants were invited to participate when they presented for
clinical care. One participant who had time to participate in the
study (study activities took about 3 hours) was chosen each day by
clinic staff and referred to study staff. In addition, patients with
neurological findings were oversampled in order to assess the
neurological examination portion of the tool—we enrolled any
individual with neurological findings referred to us by study staff.
Participants who could not speak English, Dholuo, or Kiswahili
well enough to participate in the neuropsychological testing were
excluded from the study.
Procedures
A diagnostic tool was administered by a HCW. The results of
this tool were compared to an expert clinical assessment
performed by study staff which included: examination by a
physician, a neuropsychological test battery administered by
expert study staff, and computed tomography of the head when
clinically indicated. The results of the expert clinical assessment
were used to identify patients meeting a modification of the
Frascati criteria for HAD [24]. The diagnostic tool was also
administered by trained staff during the expert assessment to assess
reliability.
Diagnostic tool (administered by HCW)
A non-physician HCW administered the diagnostic tool
(Appendix S1) which consisted of a brief history and neurological
examination, cognitive assessment based on the International HIV
Dementia Scale (IHDS) [9] and assessment of functional status.
The HCW were blinded to the results of the expert clinical
assessment performed by study staff. To assess reliability, all
components of the cognitive testing portion of the diagnostic tool
(C4–C8) were also administered by expert study staff. Since the
tool was administered by HCW during the course of their usual
clinical duties, the timing of tool administration was planned in
such a way as to minimize impact to clinic flow. The expert
clinical assessment was conducted after the HCW administered
the diagnostic tool in 19/30 cases.
The eighteen non-physician HCW who participated in this
study were either clinical officers or nurses on the staff of FACES.
Clinical officers receive three to four years of post-secondary
school education and are comparable to physician’s assistants in
the United States. Nurses receive two to four years of post-
secondary school education. Since we sought to explore the utility
of this diagnostic tool in a setting we felt mimicked ‘‘real-life’’
practice settings for primary HCW, we did not provide additional
training specific to this tool to participating HCW. All the HCW
who participated in the study have received HIV-specific training
and ongoing mentorship through FACES. At the time of the study,
one investigator (ACM) had been providing training and
mentorship in HIV Neurology for six months at the study site
and had conducted several trainings on the neurological
examination to clinicians and nurses at our study site using a
format quite similar to the neurological examination contained in
the diagnostic tool. Most of the tests included in the cognitive
assessment are part of the Kenyan National Guidelines, and in
theory, all HCW had received training on their administration.
Expert clinical assessment (administered by study team)
Each participant underwent a standardized clinical examina-
tion, a neuropsychological test battery, and computed tomography
of the head when clinically indicated, and classification of
dementia.
Examination. Each participant underwent a standardized
examination which included: a detailed history; full medical
examination; subjective and objective examination of mental state
and cognition using the Patients Assessment of Own Functioning
Inventory (PAOFI) [25] and the Mini-Mental State Examination
[26]; detailed examination of all cranial nerves except the olfactory
nerve; fundoscopy; motor examination and strength testing in 20
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different muscle groups; examination of light touch, pinprick and
temperature at 14 predefined areas, as well as assessment of distal
joint position and vibration sense; six predefined tests of
coordination and motor function; assessments of five deep
tendon reflexes, the plantar reflex, four frontal release reflexes;
gait exam with seven specific observations, and Romberg test. The
two non-neurologists (DC and JK) who performed the neurologic
examinations underwent extensive training including numerous
full observed examinations by the principal investigator (AM).
Computerized tomography (CT) of the brain was performed in
four participants with likely HAD or focal findings on neurological
exam to rule out a mass lesion, infarct, or other process which
might mimic the clinical and neuropsychological findings of HAD.
Several measures of functional status were used including the
PAOFI, Activities of Daily Living [27], Instrumental Activities of
Daily Living [28], and the Physical Function, Role Function, and
Role limitations due to Physical Health of the Medical Outcomes
Study [29]. Most of these have not been formally tested in a
Kenyan population, so the answers to all these questions were
integrated by the physician or neurologist in assigning a
Karnovsky Performance Scale score [30] intended to represent
limitations in function due only to cognitive impairment.
Neuropsychological test battery. The neuropsychological
test battery was administered by expert study staff and assessed
attention/working memory (Digit Span [31]), category fluency
(Animals, First Names [32]) executive function (Block Design [31],
Color Trails 2 [33]), speed of information processing (Digit Symbol
[31], Color Trails 1 [33]), verbal and visual learning and memory
(WHO/UCLA Auditory Verbal Learning Test [AVLT] [32,33]
and Revised Brief Visuospatial Memory Test [BVMT] [34]), and
psychomotor speed (Grooved Pegboard [35], Finger Tapper [36],
Timed Gait [37]). In addition, two established screening tests, the
MMSE [26] and the International HIV Dementia Scale (IHDS) [9]
were administered. As described previously, the MMSE was
administered by the physician as part of the examination.
Neuropsychological testing was performed in the patient’s
preferred language (either English, Kiswahili, or Dholuo). The
study staff member administering neuropsychological tests was
fluent in the preferred language.
As no published normative data was available from Kenyan or
East African populations, normative values from general United
States populations were used to convert raw scores to standardized
scores (Z-scores) [31,34–40]. The exception was for category
fluency in which normative data from an African American U.S.
population was used as data from a general population was not
available [38]. Z-scores were calculated so that negative Z scores
always represented worse performance on a test. A composite
standardized score was generated by averaging the mean
standardized score for each individual test.
Classification of Dementia. The Frascati criteria for HAD
were modified slightly and implemented as follows [24]: for an
individual to be classified with HAD, they had to have (1)
neuropsychological test scores .2 standard deviations (SD) below
the mean in at least two different cognitive domains, and (2) major
functional decline due to cognitive impairment in the opinion of the
examining physician. We omitted a second criterion of impairment on
neuropsychological tests (a score.1 SDmean in one cognitive domain
and a score of.2.5 SD below themean in another) because we did not
have a culturally appropriate normative sample and nearly all of our
participants scored .1SD below the mean in at least one cognitive
domain. For an assessment of the performance of neuropsychological
tests we divided our sample into two additional categories. Individuals
who did not meet the above criteria for abnormal neuropsychological
tests were classified as normal. The remaining individuals who met the
neuropsychological test criteria for cognitive impairment as described
above did not have no major impairments in functional status were
grouped and classified as Asymptomatic Neurocognitive Impairment
(ANI)/Mild Neurocognitive Disorder (MND). Subjects were classified
by a physician and a neurologist and final diagnoses were decided by
consensus. The physician and neurologist were blinded to the results of
the diagnostic tool administered by the HCW.
Analytic Approach and Statistical Methods
Descriptive statistics were generated for demographic and
clinical characteristics. Student’s T-tests were used to compare
means and Fisher’s exact test to compare proportions between
individuals with and without HAD. We also compared raw and
standardized scores on neuropsychological tests across categories
of HAND and between individuals with and without moderate to
severe depression. Sensitivity, specificity, receiver operator char-
acteristic (ROC) curves were generated for the diagnostic tool.
Quadratic-weighted kappa statistics were generated for the overall
score and individual items on the cognitive portion of the
diagnostic tool (Section C4–C8) to compare agreement between
the HCW and expert study staff.
Statistical analyses were performed using Stata10.0 (StataCorp,
College Station, Texas). A significance level of p#.05 was used.
Ethics Statement
The study protocol was approved by the University of
California San Francisco (UCSF) Committee on Human Research
and the National Ethical Review Committee (ERC) of the Kenya
Medical Research Institute (KEMRI). Written informed consent
was obtained from each participant.
Results
Expert Clinical Assessment
The mean age of the sample was 39 years and 57% were male.
The mean CD4 T-cell count was 323 cells/mL, 60% had WHO
Stage 3 or 4 disease, and 50% had less than a secondary school
education (Table 1). Nearly 23% (7/30) of participants had
moderate or severe depression using the Patient Assessment of
Health Questionnaire (PHQ9) [41]. In general, functional status
measures demonstrated mild impairments. There were no
significant differences in demographic, clinical, functional status
or psychiatric characteristics between individuals with and without
HAD though this should be interpreted with caution given small
sample sizes.
Among our pilot sample, 20% (6/30) were diagnosed with HAD
based on the expert clinical assessment. An additional 33% (10/
30) were classified as normal. The remaining 47% (14/30)
individuals were grouped and classified as mild neurocognitive
impairment. Among the individuals classified as normal, there
were five individuals with abnormal neurological examinations
potentially localizing to the central nervous system. Findings
included: (1) unsteady gait and asymmetric ataxia (left worse than
right); (2) multiple cranial neuropathies (III, IV, V, VI, VII, IX, X)
with subtle left sided weakness and left cerebellar signs; (3)
parkinsonism; (4) a large left retro-orbital mass, and (5) a history of
right-sided weakness with no objective findings on examination.
Of these individuals, three individuals were referred for computed
tomography (CT) of the head. The CT findings were as follows: (1)
Marked cerebellar volume loss including the middle cerebellar
peduncle and pons but sparing the medullary pyramids; (2)
periventricular hypothalamic lesion and marked edema, likely
CNS lymphoma, (3) diffuse volume loss and small caudate heads.
The individual with a left retro-orbital mass had a CT scan
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previously that demonstrated a sizeable mass in the retro-orbital
space. A fourth individual who had markedly poor performance
on neuropsychological tests and who was ultimately classified as
having HAD, also underwent a CT scan which was normal.
Neuropsychological tests and HAND. We then reviewed
the performance of our neuropsychological test battery, excluding
the four individuals listed above with abnormal neurological
examinations. As the level of cognitive impairment increased,
mean raw scores worsened on nearly all of the individual
neuropsychological tests chosen for this test battery (Table 2).
Similarly, individuals with higher levels of cognitive impairment
had worse performance on the MMSE and IHDS. The one
exception was Category Fluency- First Names where mean raw
scores among individuals with mild neurocognitive impairment
were higher than scores among normal individuals. Mean
standardized scores also worsened on all tests except Category
Fluency-First Names as the level of cognitive impairment
increased (Figure 1). The composite score, an average of the
standardized scores for all the tests, decreased from -0.6 [SD: 0.76]
among normal individuals to -2.16 [SD: 1.63] among individuals
with HAD. The greatest magnitude differences on standardized
scores between normal individuals and those with HAD were on
the tests of Motor Skills and Color Trails 1. Of note, among
individuals classified as normal, the mean standardized score was
#21 in Block Design, Digit Symbol, and all the tests of Motor
Skills.
Neuropsychological tests and depression. Individuals
with moderate to severe depression on the PHQ-9 instrument
were not more likely to have a score of #22 on our novel
diagnostic tool using Fisher’s exact (.39). They were more likely to
Table 1. Baseline characteristics of study participants comparing individuals with and without HIV-associated dementia.
Overall (n = 30) No dementia (n=24) HIV-associated dementia (n =6)
Demographic Characteristics
Age [mean (SD)] 39 (10) 47 (6.8) 37 (10)
Male [% (n)] 57% (17) 50% (12) 83% (5)
Marital Status [% (n)]
Never Married 13% (4) 17% (4) 0%
Married 63% (19) 54% (13) 83% (5)
Widowed 20% (6) 21% (5) 17% (1)
Divorced/separated 4% (1) 4% (1) 0%
Highest level of education achieved [% (n)]
Less than primary 23% (7) 21% (5) 33% (2)
At least primary 27% (8) 29% (7) 17% (1)
Secondary 37% (11) 42% (10) 17% (1)
More than secondary 14% (4) 12% (2) 33% (2)
Socio-economic status
Electricity in dwelling [% (n)] 37% (11) 38% (9) 33% (2)
Running water in dwelling [% (n)] 13% (4) 13% (3) 17% (1)
Selected clinical characteristics
WHO Stage currently [% (n)]
Stage 1 13% (4) 13% (3) 17% (1)
Stage 2 27% (8) 29% (7) 17% (1)
Stage 3 37% (11) 33% (8) 50% (3)
Stage 4 23% (7) 25% (6) 17 (1)
Nadir CD4 cell count [mean (SD)] 198 (150) 215 (157) 127 (103)
Current CD4 cell count [mean (SD)] 323 (211) 337 (227) 268 (134)
Moderate to severe depression [%(n)]* 23% (7) 21% (5) 33% (2)
Functional Status Measures
Karnovsky Performance Scale [mean (SD)]Range (0–100) 92 (20) 92 (22) 91 (4.1)
Activities of Daily Living (ADL)[mean (SD)] Range (0–4) 4 (0) 4 (0) 4 (0)
Independent ADL [mean (SD)] Range (0–8) 7.8 (0.7) 7.8 (0.7) 8 (0)
Physical Function[mean (SD)] Range (0–100) 89(19) 97 (4) 87 (201)
Role Limitation due to Physical Function
[mean (SD)] Range (0–100)
82 (5.1) 80 (31) 89 (16)
Patient assessment of own functioning
inventory (PAOFI){ [mean (SD)] Range (0–165)
12 (14) 13 (15) 12 (5.9)
*Score $10 on Patient Health Questionnaire (PHQ9);
{PAOFI- a score of 0 reflects no impairment.
doi:10.1371/journal.pone.0032898.t001
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have a score of #10 on the IHDS using Fisher’s exact (.02). In
general, individuals with moderate to severe depression had
significantly lower mean standardized scores on all the
neuropsychological tests from the Psychomotor domain
(Grooved Pegboard (Dom/ND), Finger Tapper (Dom/ND),
Timed Gait) as well as the verbal learning and memory domain
(AVLT Total Score, AVLT Score Trial V, AVLT DR) (data not
shown). The remainder of the tests did not demonstrate significant
differences in mean standardized scores between with individuals
with and without moderate to severe depression: Category fluency
(animals and names), Color Trails 1 & 2, Block Design, Digit
Symbol, Digit Span, BVMT, BVMT-DR (data not shown).
Novel Diagnostic tool and HAD
Among this sample, the diagnostic tool determined that 53%
(16/30) of our sample had HAD. An ROC curve was generated
to assess the utility of the diagnostic tool in identifying individuals
with HAD. A cut-off score of #22 (maximum=26) resulted in a
sensitivity of 63%, specificity of 67% and accuracy of 63%.
Kappa statistics were used to evaluate agreement between the
neuropsychological tests administered by a HCW as compared to
expert study staff in Section C (cognitive portion) of the
diagnostic tool. An expert examiner administered the cognitive
components of the diagnostic tool after the HCW in 19/30 cases;
in the remaining 11 cases, the expert examiner administered the
diagnostic tool first. As shown in Table 3, moderate agreement
was observed for C6: Serial Operations and C7: Category
Fluency. Fair agreement was observed for C8: Recall and the
total neuropsychological test score (C score). There was poor
agreement for C4: Finger tapping and C5: Luria sequence.
Despite poor agreement on 2 of 3 items taken from the IHDS,
there was fair agreement on the overall score of the IHDS.
Similarly there was poor agreement between Section B
(neurological examination portion) of the diagnostic tool and
the neurological examination conducted by the study physician;
four individuals found to have an abnormal neurological exam by
the study physician were not similarly classified when examined
by the HCW administering the diagnostic tool.
Table 2. Comparison of mean raw scores on individual tests comprising neuropsychological test battery by level of cognitive
impairment among HIV-infected individuals.*
Normal ANI, MND HAD
(n=6) (n =14) (n=6)
Mean SD Mean SD Mean SD
Category Fluency
Animals 20.8 (5.5) 16.6 (3.8) 14.8 (4.1)
First Names 23 (4.3) 23.1 (5.4) 19.3 (5.5)
Executive Function
Color Trails 2{ 118.8 (28.9) 159.2 (46.5) 169.5 (42.9)
Block Design 16.2 (7.3) 11.8 (2.5) 7.3 (3.3)
Speed of Information Processing
Digit Symbol 51.8 (12) 34.5 (10.9) 23 (14.0)
Color Trails 1{ 51.2 (9.3) 76.3 (29.0) 99.3 (28.9)
Attention/Working Memory
Digit Span 13.8 (2.1) 12.2 (3.2) 11.2 (4.7)
Visual and Verbal Learning
AVLT Total Score 52.8 (3.2) 45.1 (8.0) 41.3 (6.7)
AVLT Trial V 12.5 (1.4) 11.1 (2.0) 9.3 (2.7)
BVMT Total Recall 21.8 (4.8) 17.4 (8.2) 13.2 (6.9)
Visual and Verbal Memory
AVLT Delayed Recall 12.2 (1.7) 9.4 (2.9) 7.7 (2.3)
BVMT Delayed Recall 8.8 (1.8) 6.3 (3.6) 5.7 (2.9)
Motor Skills
Finger Tapper (D) 44.7 (5.7) 38.3 (5.7) 34.4 (10.1)
Finger Tapper (ND) 38.2 (6.4) 33.8 (4.1) 33.5 (7.7)
Grooved Pegboard (D){ 71.2 (10.3) 91.7 (25.6) 111.3 (27.8)
Grooved Pegboard (ND){ 82.5 (12.3) 93.9 (14.5) 132.5 (30.2)
Timed Gait{ 11 (1.5) 13.3 (2.3) 13.5 (2.8)
Batteries
International HIV Dementia Scale 11 (1.7) 9.9 (1.9) 8.5 (1.8)
Mini-Mental State Examination 27.5 (1.9) 27.1 (2,1) 26.5 (2.2)
*Four individuals with non-HIV related neurologic diagnoses that affected performance on neuropsychological tests were dropped from this analysis.
{Higher scores indicate worse performance. Abbreviations: ANI: Asymptomatic Neurocognitive Impairment; D =Dominant; HAD: HIV-associated dementia; MND: Mild
Neurocognitive Disorder; ND=Non-dominant.
doi:10.1371/journal.pone.0032898.t002
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Discussion
Expert Clinical Assessment
This convenience sample of individuals presenting for routine
clinical care in Kenya was comparable to larger community-based
samples from sub-Saharan Africa [42–44]. In addition, during the
month that we were recruiting for this study, we encountered
several individuals with severe neurological disorders—highlight-
ing the importance of improving neurological training for primary
HIV healthcare workers in resource-limited settings.
Neuropsychological Test Battery and HAND. Mean raw
and standardized scores (Z-scores) on many tests in our
neuropsychological test battery demonstrated large magnitude
differences between individuals with and without HAND. Our
results demonstrated the typical pattern of HIV associated
cognitive impairment with one notable exception. Our results
were similar to prior studies in that we observed large differences
in scores in the domains of executive function (Block Design, Color
Trails 2,) speed of information processing (Digit Symbol, Color
Trails), and motor/psychomotor function (Grooved Pegboard,
Finger Tapper, and Timed Gait) [45–49].
In contrast to previous studies, tests of motor or psychomotor
performance in the non-dominant hand did not demonstrate
larger magnitude differences in mean raw or standardized scores
and thus may not be more sensitive and reliable in diagnosing
HAND [10,22]. This may be related to the small sample size or
cultural differences in interpreting test instructions. For example,
we noted that many study subjects did not work as quickly as they
could after being given the instruction ‘‘as fast as you can’’ and
that additional explanation was necessary to elicit maximal effort
on timed tests. These differences warrant further exploration with
a larger sample size and culturally specific normative data before
any conclusions can be drawn.
We found large differences in mean raw and standardized
scores for AVLT and BVMT-R among individuals with and
without HAND although difficulty with verbal learning and
memory are thought to be less characteristic of HAND [50]. These
findings were comparable to those reported from a Ugandan study
which used AVLT as part of their test battery [22]. Whether this
represents a different pattern of cognitive deficits unique to sub-
Saharan Africa, is related to literacy levels, or is a function of
overlapping cognitive domains (e.g. low scores on AVLT could be
caused by poor attention) remains to be seen.
One important finding is that among individuals classified as
normal, performance on several tests was substantially lower than
our U.S. normative population. Mean standardized scores on
Block Design, Digit Symbol, and all the tests of motor skills were
less than or equal to one standard deviation below the normative
mean. Strictly applying the AAN Frascati criteria [24] could result
in a diagnosis of mild cognitive impairment at this level of
Figure 1. Comparison of mean standardized scores on individual neuropsychological tests comprising neuropsychological test
battery and a composite measure by level of cognitive impairment among HIV-infected individuals.
doi:10.1371/journal.pone.0032898.g001
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performance, again highlighting the need for a culturally
appropriate normative sample.
Novel Diagnostic Tool and HAD
As administered in this pilot sample, the novel diagnostic tool
had lower sensitivity and specificity than studies using similar
tools—the IHDS in Uganda [9] and a culturally adapted version
of the MMSE in Zambia [3]. This study differed from those
studies in several important ways. First, in this study, a non-
physician HCW administered the diagnostic tool without
additional training while in the Ugandan study, a highly trained
physician administered the IHDS [9]. Second, we introduced a
novel assessment tool while in the Zambian study, the Zambian
version of the MMSE was familiar to the primary HCW from
their clinical training [3]. In the same study, the HIV Dementia
Scale (HDS) [51] was also administered by trained HCW. Even
with training, frequent errors were reported in the test which
may have been due in part to poor administration by HCW
[42].
As described in the methods section, the HCW participating in
this study had received some general training in the neurological
examination and in HIV care according to Kenya National
Guidelines which includes many of the cognitive tests contained in
the diagnostic tool. In this study, we chose not to provide
additional training specific to the tool for two reasons: (1) to assess
training needs for this tool, and (2) to assess the feasibility of
implementation in a decentralized health care system where most
care is provided by non-physician HCW and wide-scale
comprehensive training is not feasible. However, the lack of
specific training likely contributed to the poor sensitivity of the
tool. For example, there was poor agreement between the non-
physician HCW and the study physician on the neurological
examination. In addition there was poor agreement on many of
the cognitive items comprising the diagnostic tool between HCW
and expert study staff.
These findings suggest that substantial training and assessments
of inter-rater agreement between physicians and non-physician
HCW will be critical prior to the use of this diagnostic tool in
routine clinical settings. Providing ongoing training is a significant
challenge in resource limited settings where staff turn-over is high.
Alternatively, choosing an assessment tool, or components of an
assessment tool, that are simpler to administer or more familiar to
primary HCW may improve diagnostic utility in routine clinical
settings. To maximize the applicability of HAD screening tools in
a decentralized system one may have to trade diagnostic
sophistication and precision—measuring the cognitive domains
most affected in HAD—to develop a tool that is easy to teach and
easy to use.
Another potential reason for the lower utility of the diagnostic
tool is inclusion of individuals with co-morbid depression who may
have been misclassified as having HAD because of poor
performance on cognitive assessments [52]. Furthermore, the
symptom (Section C, items 1 and 2) and functional status questions
(Section D) on the tool showed little variation and likely added
little to the ability of the tool to discriminate between those with
and without HAD (data not shown). Finally, although the patient
populations were demographically similar, cultural differences
between our study site in Kenya and those in Zambia and Uganda
may have contributed to the lower utility in our population.
Strengths and Limitations
A strength of our study is that it was performed in an outpatient
HIV care setting typical of others in sub-Saharan Africa. In
addition, the diagnostic tool was administered by non-physician
HCW which improves the generalizability of our results. However,
this study was limited by the small sample size and the lack of
training for non-physician HCW administering the tool. Also, the
neuropsychological test instructions were not standardized but
were interpreted by study staff fluent in those languages. In
addition, the expert clinical assessment by study staff did not
include a lumbar puncture to evaluate for other infections of the
central nervous system or MRI to look for other focal lesions of the
brain. In place of these procedures, which are not available in our
setting, we performed a detailed medical and neurological
examination. We also performed CT of the head in individuals
with HAD or an abnormal neurological examination that localized
to the central nervous system.
It is important to note that a major limitation of this study was
the lack of Kenyan normative data. Since performance on many
neuropsychological tests is sensitive to cultural, linguistic, educa-
tional, gender and age differences, it is not known if (or to what
extent) the tests scores of an HIV uninfected Kenyan normal
population would differ from this HIV infected population. Our
study demonstrates that many normal individuals receive scores in
the impaired range on several of the neuropsychological tests,
suggesting that normative data from the U.S. is not appropriate,
and highlighting the need for culturally appropriate normative
data.
Conclusion
Pilot testing suggests that substantial training and formal
evaluations of training adequacy will be critical to enable primary
HCW to reliably administer a brief diagnostic tool for HAD that
contains cognitive tests and a neurological examination. Alterna-
tively, selecting the simpler or more familiar components from
more sophisticated screening or diagnostic tools may improve the
Table 3. Agreement between non-physician health care worker and a expert examiner on cognitive tests in the diagnostic tool.
Neuropsychological test Items from diagnostic tool (Section C) Quadratic weighted Kappa
C4: Finger Tapping 0.03
C5: Luria sequence 0.05
C6: Serial Operations 0.47
C7: Category fluency (animals) 0.65
C8: Recall 0.25
C score (Sum of C1–C8) 0.32
International HIV Dementia Scale total score (Sum of C4, C5,C8) 0.26
doi:10.1371/journal.pone.0032898.t003
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diagnostic utility in routine clinical settings in a decentralized
system of care. Finally, normal individuals frequently have
standardized scores in the impaired range using our neuropsy-
chological test battery. Thus, culturally specific normative values
for neuropsychological tests are critical prior to widespread clinical
or research use for the diagnosis of HIV-associated neurocognitive
disorders.
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